New combo tackles relapsed leukemia after stem cell transplant
NCT ID NCT02684162
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called guadecitabine combined with donor lymphocyte infusions in 55 patients whose acute myeloid leukemia or myelodysplastic syndrome came back after a stem cell transplant. The goal was to see if the drug could help the donor immune cells fight the cancer while reducing side effects. The trial has completed, and researchers measured how many patients achieved complete remission and how long they survived.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guadecitabine (a drug) and donor lymphocyte infusion (white blood cells from the donor)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients whose leukemia or MDS returns after a stem cell transplant.
- What could go wrong
- This is a small, completed Phase II trial, so results are not yet confirmed in larger studies. The treatment may cause serious side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?